vs
Knife River Corp（KNF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Knife River Corp的1.0倍（$772.1M vs $755.1M），Revvity净利率更高（12.7% vs 4.2%，领先8.5%），Knife River Corp同比增速更快（14.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $138.2M），过去两年Knife River Corp的营收复合增速更高（51.4% vs 9.0%）
哥伦比亚河刀具工具公司（CRKT）是1994年成立的美国刀具企业，总部位于美国俄勒冈州图拉丁，主营各类刀具相关产品，目前由罗德·布雷默担任总裁兼销售主管，佩吉·布雷默担任财务主管。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KNF vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$755.1M
营收增速更快
KNF
高出9.0%
5.9%
净利率更高
RVTY
高出8.5%
4.2%
自由现金流更多
RVTY
多$23.6M
$138.2M
两年增速更快
KNF
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $755.1M | $772.1M |
| 净利润 | $32.0M | $98.4M |
| 毛利率 | 19.2% | — |
| 营业利润率 | 8.6% | 14.5% |
| 净利率 | 4.2% | 12.7% |
| 营收同比 | 14.9% | 5.9% |
| 净利润同比 | 37.6% | 3.9% |
| 每股收益（稀释后） | $0.56 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KNFRVTY
| Q4 25 | $755.1M | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $833.8M | $720.3M | ||
| Q1 25 | $353.5M | $664.8M | ||
| Q4 24 | $657.2M | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $806.9M | $691.7M | ||
| Q1 24 | $329.6M | $649.9M |
净利润KNFRVTY
| Q4 25 | $32.0M | $98.4M | ||
| Q3 25 | $143.2M | $46.7M | ||
| Q2 25 | $50.6M | $53.9M | ||
| Q1 25 | $-68.7M | $42.2M | ||
| Q4 24 | $23.3M | $94.6M | ||
| Q3 24 | $148.1M | $94.4M | ||
| Q2 24 | $77.9M | $55.4M | ||
| Q1 24 | $-47.6M | $26.0M |
毛利率KNFRVTY
| Q4 25 | 19.2% | — | ||
| Q3 25 | 23.6% | 53.6% | ||
| Q2 25 | 18.9% | 54.5% | ||
| Q1 25 | -2.7% | 56.5% | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 24.7% | 56.3% | ||
| Q2 24 | 21.8% | 55.7% | ||
| Q1 24 | 2.0% | 54.6% |
营业利润率KNFRVTY
| Q4 25 | 8.6% | 14.5% | ||
| Q3 25 | 17.9% | 11.7% | ||
| Q2 25 | 10.6% | 12.6% | ||
| Q1 25 | -23.4% | 10.9% | ||
| Q4 24 | 6.7% | 16.3% | ||
| Q3 24 | 18.9% | 14.3% | ||
| Q2 24 | 14.5% | 12.4% | ||
| Q1 24 | -16.3% | 6.8% |
净利率KNFRVTY
| Q4 25 | 4.2% | 12.7% | ||
| Q3 25 | 11.9% | 6.7% | ||
| Q2 25 | 6.1% | 7.5% | ||
| Q1 25 | -19.4% | 6.4% | ||
| Q4 24 | 3.5% | 13.0% | ||
| Q3 24 | 13.4% | 13.8% | ||
| Q2 24 | 9.7% | 8.0% | ||
| Q1 24 | -14.5% | 4.0% |
每股收益（稀释后）KNFRVTY
| Q4 25 | $0.56 | $0.86 | ||
| Q3 25 | $2.52 | $0.40 | ||
| Q2 25 | $0.89 | $0.46 | ||
| Q1 25 | $-1.21 | $0.35 | ||
| Q4 24 | $0.42 | $0.77 | ||
| Q3 24 | $2.60 | $0.77 | ||
| Q2 24 | $1.37 | $0.45 | ||
| Q1 24 | $-0.84 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $73.8M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $1.6B | $7.3B |
| 总资产 | $3.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.71× | — |
8季度趋势，按日历期对齐
现金及短期投资KNFRVTY
| Q4 25 | $73.8M | $919.9M | ||
| Q3 25 | $30.7M | $931.4M | ||
| Q2 25 | $26.6M | $991.8M | ||
| Q1 25 | $86.1M | $1.1B | ||
| Q4 24 | $236.8M | $1.2B | ||
| Q3 24 | $220.4M | $1.2B | ||
| Q2 24 | $15.5M | $2.0B | ||
| Q1 24 | $128.4M | $1.7B |
总债务KNFRVTY
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $677.4M | — | ||
| Q3 24 | $678.5M | — | ||
| Q2 24 | $679.5M | — | ||
| Q1 24 | $680.6M | — |
股东权益KNFRVTY
| Q4 25 | $1.6B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.5B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.5B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.3B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产KNFRVTY
| Q4 25 | $3.7B | $12.2B | ||
| Q3 25 | $3.7B | $12.1B | ||
| Q2 25 | $3.6B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $2.9B | $12.8B | ||
| Q2 24 | $2.7B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
负债/权益比KNFRVTY
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 0.83× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | 0.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $195.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $138.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 18.3% | 21.0% |
| 资本支出强度资本支出/营收 | 7.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 6.12× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-69.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流KNFRVTY
| Q4 25 | $195.9M | $182.0M | ||
| Q3 25 | $250.4M | $138.5M | ||
| Q2 25 | $-42.6M | $134.3M | ||
| Q1 25 | $-125.3M | $128.2M | ||
| Q4 24 | $172.4M | $174.2M | ||
| Q3 24 | $239.7M | $147.9M | ||
| Q2 24 | $-46.6M | $158.6M | ||
| Q1 24 | $-43.2M | $147.6M |
自由现金流KNFRVTY
| Q4 25 | $138.2M | $161.8M | ||
| Q3 25 | $188.7M | $120.0M | ||
| Q2 25 | $-196.2M | $115.5M | ||
| Q1 25 | $-200.2M | $112.2M | ||
| Q4 24 | $127.2M | $149.8M | ||
| Q3 24 | $216.1M | $125.6M | ||
| Q2 24 | $-106.5M | $136.6M | ||
| Q1 24 | $-86.9M | $129.7M |
自由现金流率KNFRVTY
| Q4 25 | 18.3% | 21.0% | ||
| Q3 25 | 15.7% | 17.2% | ||
| Q2 25 | -23.5% | 16.0% | ||
| Q1 25 | -56.6% | 16.9% | ||
| Q4 24 | 19.3% | 20.5% | ||
| Q3 24 | 19.6% | 18.4% | ||
| Q2 24 | -13.2% | 19.7% | ||
| Q1 24 | -26.4% | 20.0% |
资本支出强度KNFRVTY
| Q4 25 | 7.6% | 2.6% | ||
| Q3 25 | 5.1% | 2.6% | ||
| Q2 25 | 18.4% | 2.6% | ||
| Q1 25 | 21.2% | 2.4% | ||
| Q4 24 | 6.9% | 3.4% | ||
| Q3 24 | 2.1% | 3.3% | ||
| Q2 24 | 7.4% | 3.2% | ||
| Q1 24 | 13.3% | 2.7% |
现金转化率KNFRVTY
| Q4 25 | 6.12× | 1.85× | ||
| Q3 25 | 1.75× | 2.97× | ||
| Q2 25 | -0.84× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 7.41× | 1.84× | ||
| Q3 24 | 1.62× | 1.57× | ||
| Q2 24 | -0.60× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KNF
| Services | $347.2M | 46% |
| Ready Mix Concrete | $88.4M | 12% |
| Contracting Services Public Sector | $80.2M | 11% |
| Aggregates | $73.9M | 10% |
| Energy Services Segment | $56.2M | 7% |
| Liquid Asphalt | $49.1M | 7% |
| Other | $43.2M | 6% |
| Asphalt | $22.7M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
